Talk to a Concierge  →
Home  ›  Resources  ›  Peking Union Medical College Hospital  ›  3D bioprinting research
Laboratory Research · English Editorial Summary

A 3D-bioprinted model recreates the bone microenvironment where prostate cancer spreads

PUMCH researchers report in the Journal of Advanced Research a 3D-bioprinted co-culture model that reproduces key features of prostate cancer bone metastases — including why tumours there resist many drugs. The work is a laboratory platform, not a clinical test or treatment.

Original report: 22 September 2026English summary: 26 September 2026Source: PUMCH official websiteEdited by Wellward China
Peking Union Medical College HospitalBeijingCancer & TumorsMen's Health & ReproductiveProstate cancerBone metastasis3D bioprinting
Source and editorial note: This is an original English summary based on PUMCH’s Chinese-language report, published 22 September 2026. It is not a full translation or an independent clinical assessment. The hospital’s source is the authority for the original announcement.
What the team built

Printing a stand-in for the bone niche

Existing lab models of prostate cancer bone metastasis have well-known limits: flat two-dimensional cultures miss the three-dimensional tissue architecture, organoids vary widely between batches, and patient-derived animal models are costly and slow. A team led by Mao Yilei and Yang Huayu at PUMCH used 3D bioprinting — which positions cells and biomaterials with high precision — to build a reproducible alternative, published in the Journal of Advanced Research.

The platform uses gelatin methacrylate (GelMA) as the main bioink. The team printed 3D prostate tumour models using two cell lines that represent different disease stages — LNCaP for androgen-dependent disease and PC-3 for castration-resistant disease — alongside a separately printed, bone-forming model derived from adipose (fat) stem cells. Co-culturing the two recreates the osteoblastic niche where prostate cancer cells settle in bone. The printed models maintained cell viability and structural stability over extended culture.

What the model showed

Key findings — laboratory observations, not patient data

In 3D culture, prostate cancer cells showed greater invasion and migration than in 2D culture, along with markedly higher resistance to chemotherapy and PARP inhibitors and stronger tolerance of androgen-deprivation conditions. When co-cultured with the bone-forming model, tumour cells became more proliferative, invasive and migratory, and less sensitive to multiple anti-cancer drugs. Notably, physically separating the two cell types — preventing direct contact — did not abolish these changes, indicating that soluble paracrine signals from the bone microenvironment drive the malignant shift.

What this is — and is not

This is a preclinical research tool. No patients were treated and no clinical results are reported; the model also uses cell lines rather than tumours from individual patients, which limits how faithfully it reflects any real cancer. Its value is mechanistic: a controllable, repeatable way to study how the bone environment promotes progression and drug resistance, and to screen candidate drugs before animal or human studies.

What comes next

The team plans to add patient-derived tumour cells, more stromal and immune cell types, and microfluidic perfusion to increase the model’s clinical relevance. Those upgrades are future work — the current platform is best understood as an early-stage research advance.

Uniform editorial cover image used across Wellward China resource summaries (placeholder)

Relevance for patients

Better lab models of bone metastasis could, over time, speed the development of drugs for advanced prostate cancer — one of the most common cancers in men worldwide. This falls under Wellward China’s Cancer & Tumors and Men's Health & Reproductive health areas. This page is general information, not medical advice.